JP2006510655A5 - - Google Patents

Download PDF

Info

Publication number
JP2006510655A5
JP2006510655A5 JP2004558241A JP2004558241A JP2006510655A5 JP 2006510655 A5 JP2006510655 A5 JP 2006510655A5 JP 2004558241 A JP2004558241 A JP 2004558241A JP 2004558241 A JP2004558241 A JP 2004558241A JP 2006510655 A5 JP2006510655 A5 JP 2006510655A5
Authority
JP
Japan
Prior art keywords
composition
less
use environment
dietary fat
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004558241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510655A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/005629 external-priority patent/WO2004052343A1/en
Publication of JP2006510655A publication Critical patent/JP2006510655A/ja
Publication of JP2006510655A5 publication Critical patent/JP2006510655A5/ja
Withdrawn legal-status Critical Current

Links

JP2004558241A 2002-12-11 2003-11-28 高脂肪環境への活性物質の制御放出 Withdrawn JP2006510655A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43286002P 2002-12-11 2002-12-11
PCT/IB2003/005629 WO2004052343A1 (en) 2002-12-11 2003-11-28 Controlled-release of an active substance into a high fat environment

Publications (2)

Publication Number Publication Date
JP2006510655A JP2006510655A (ja) 2006-03-30
JP2006510655A5 true JP2006510655A5 (enExample) 2006-07-13

Family

ID=32508002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004558241A Withdrawn JP2006510655A (ja) 2002-12-11 2003-11-28 高脂肪環境への活性物質の制御放出

Country Status (18)

Country Link
US (1) US20040121015A1 (enExample)
EP (1) EP1572163A1 (enExample)
JP (1) JP2006510655A (enExample)
KR (1) KR20050088311A (enExample)
CN (1) CN1726012A (enExample)
AR (1) AR042340A1 (enExample)
AU (1) AU2003283688A1 (enExample)
BR (1) BR0317275A (enExample)
CA (1) CA2508722A1 (enExample)
CO (1) CO5570656A2 (enExample)
MX (1) MXPA05005812A (enExample)
NO (1) NO20053068L (enExample)
NZ (1) NZ539915A (enExample)
PL (1) PL377479A1 (enExample)
RU (1) RU2308263C2 (enExample)
TW (1) TWI257302B (enExample)
WO (1) WO2004052343A1 (enExample)
ZA (1) ZA200503812B (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
US8058291B2 (en) * 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
DE602006004558D1 (de) * 2005-01-28 2009-02-12 Pfizer Prod Inc Schnell zerfallendes mikroporöses bindemittel und herstellungsverfahren dafür
EP1909770B1 (en) * 2005-02-22 2013-03-20 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
EP2392258B1 (en) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-informatics system
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US8730031B2 (en) 2005-04-28 2014-05-20 Proteus Digital Health, Inc. Communication system using an implantable device
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2007028035A2 (en) 2005-09-01 2007-03-08 Proteus Biomedical, Inc. Implantable zero-wire communications system
KR20140018439A (ko) 2006-05-02 2014-02-12 프로테우스 디지털 헬스, 인코포레이티드 환자 주문형 치료법
WO2008066617A2 (en) 2006-10-17 2008-06-05 Proteus Biomedical, Inc. Low voltage oscillator for medical devices
JP5916277B2 (ja) * 2006-10-25 2016-05-11 プロテウス デジタル ヘルス， インコーポレイテッド 摂取可能な制御活性化識別子
WO2008063626A2 (en) 2006-11-20 2008-05-29 Proteus Biomedical, Inc. Active signal processing personal health signal receivers
DK3785599T3 (da) 2007-02-01 2022-11-07 Otsuka Pharma Co Ltd Spiselige eventmarkersystemer
CA3000257C (en) * 2007-02-14 2020-04-28 Proteus Digital Health, Inc. In-body power source having high surface area electrode
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
EP2063771A1 (en) 2007-03-09 2009-06-03 Proteus Biomedical, Inc. In-body device having a deployable antenna
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
FI2192946T3 (fi) 2007-09-25 2022-11-30 Elimistön sisäinen laite, jossa on virtuaalinen dipolisignaalinvahvistus
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
KR100920106B1 (ko) * 2007-11-14 2009-10-01 경북대학교 산학협력단 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치
ES2661739T3 (es) 2007-11-27 2018-04-03 Proteus Digital Health, Inc. Sistemas de comunicación transcorporal que emplean canales de comunicación
ES2840773T3 (es) 2008-03-05 2021-07-07 Otsuka Pharma Co Ltd Sistemas y marcadores de eventos ingeribles de comunicación multimodo
US20110009715A1 (en) 2008-07-08 2011-01-13 David O' Reilly Ingestible event marker data framework
JP5715564B2 (ja) 2008-08-13 2015-05-07 プロテウス デジタル ヘルス， インコーポレイテッド 摂取可能デバイスおよびそれを生成する方法
MX385591B (es) 2008-08-15 2025-03-18 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
CN102245259B (zh) * 2008-11-13 2013-06-12 普罗秋斯数字健康公司 可摄入的治疗激活器系统及方法
KR101126153B1 (ko) 2008-12-11 2012-03-22 프로테우스 바이오메디컬, 인코포레이티드 휴대용 일렉트로비세로그래피 시스템을 사용한 위장 기능의 평가 및 그 사용 방법
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
TWI424832B (zh) 2008-12-15 2014-02-01 Proteus Digital Health Inc 與身體有關的接收器及其方法
JP2012514799A (ja) 2009-01-06 2012-06-28 プロテウス バイオメディカル インコーポレイテッド 摂取に関連するバイオフィードバックおよび個別薬物療法の方法およびシステム
US8597186B2 (en) 2009-01-06 2013-12-03 Proteus Digital Health, Inc. Pharmaceutical dosages delivery system
US8540664B2 (en) 2009-03-25 2013-09-24 Proteus Digital Health, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
SG10201810784SA (en) 2009-04-28 2018-12-28 Proteus Digital Health Inc Highly Reliable Ingestible Event Markers And Methods For Using The Same
EP2432458A4 (en) 2009-05-12 2014-02-12 Proteus Digital Health Inc ACCEPTABLE EVENT MARKER WITH SUGAR COMPONENT
WO2011017502A2 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
EP2467707A4 (en) 2009-08-21 2014-12-17 Proteus Digital Health Inc DEVICE AND METHOD FOR MEASURING BIOLOGICAL PARAMETERS
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
UA109424C2 (uk) 2009-12-02 2015-08-25 Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
WO2011094606A2 (en) 2010-02-01 2011-08-04 Proteus Biomedical, Inc. Data gathering system
CN102869677B (zh) 2010-02-17 2015-07-08 硬木药品公司 胃肠病症的治疗
SG10201502720VA (en) 2010-04-07 2015-05-28 Proteus Digital Health Inc Miniature ingestible device
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
CA2808091C (en) 2010-08-11 2019-05-21 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
EP2642983A4 (en) 2010-11-22 2014-03-12 Proteus Digital Health Inc DEVICE INGREABLE WITH PHARMACEUTICAL PRODUCT
EP2683291B1 (en) 2011-03-11 2019-07-31 Proteus Digital Health, Inc. Wearable personal body associated device with various physical configurations
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
BR112014001397A2 (pt) 2011-07-21 2017-02-21 Proteus Biomedical Inc dispositivo, sistema e método de comunicação móvel
JP6312592B2 (ja) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
CN104487347B (zh) 2012-07-23 2017-09-01 普罗秋斯数字健康公司 用于制造包括电子器件的片剂的方法和系统
DK2910013T3 (en) 2012-10-18 2018-08-06 Proteus Digital Health Inc Apparatus, system and method for adaptive optimization for power output and transmit power in a power source for a communication device
TWI659994B (zh) 2013-01-29 2019-05-21 美商普羅托斯數位健康公司 高度可膨脹之聚合型薄膜及包含彼之組成物
WO2014151929A1 (en) 2013-03-15 2014-09-25 Proteus Digital Health, Inc. Personal authentication apparatus system and method
WO2014197402A1 (en) 2013-06-04 2014-12-11 Proteus Digital Health, Inc. System, apparatus and methods for data collection and assessing outcomes
JP5941240B2 (ja) 2013-03-15 2016-06-29 プロテウス デジタル ヘルス， インコーポレイテッド 金属検出器装置、システム、および方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
CA2924815C (en) 2013-09-20 2017-06-20 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
JP2016537924A (ja) 2013-09-24 2016-12-01 プロテウス デジタル ヘルス， インコーポレイテッド 事前に正確に把握されていない周波数において受信された電磁信号に関する使用のための方法および装置
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
BR112019000861B1 (pt) 2016-07-22 2020-10-27 Proteus Digital Health, Inc dispositivo eletrônico
CA3041041A1 (en) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers
CN111214456A (zh) * 2020-03-10 2020-06-02 浙江普利药业有限公司 伏立康唑干混悬剂及其制备方法
WO2022023463A1 (en) * 2020-07-30 2022-02-03 Faes Farma, S.A. Decongestant drug delivery system
CN112198274B (zh) * 2020-11-02 2022-04-05 北京市理化分析测试中心 一种检测氨酚伪麻片中盐酸伪麻黄碱的方法
CN113514579A (zh) * 2021-06-23 2021-10-19 远大生命科学(武汉)有限公司 一种依托咪酯乳状注射液体外释放曲线的测定方法
CN115647000B (zh) * 2022-10-26 2025-06-27 华能阜新风力发电有限责任公司 一种基于低温热解的风电叶片回收方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4203439A (en) * 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
GB8926639D0 (en) * 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
ZA932272B (en) * 1992-03-30 1993-10-19 Alza Corp Viscous suspensions of controlled-release drug particles
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US6004582A (en) * 1997-05-30 1999-12-21 Laboratorios Phoenix U.S.A, Inc. Multi-layered osmotic device
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system

Similar Documents

Publication Publication Date Title
JP2006510655A5 (enExample)
RU2308263C2 (ru) Контролируемое высвобождение активного вещества в среду с высоким содержанием жира
ES2568746T3 (es) Sistemas de liberación pulsátil controlada
CN103209681B (zh) 纳米颗粒薄膜递送系统
Ahad et al. Transdermal delivery of antidiabetic drugs: formulation and delivery strategies
US7037526B1 (en) Film preparation for biphasic release of pharmacologically active or other substances
HU227971B1 (en) Tramadol multiple unit formulations and process for producing them
BRPI0309142B1 (pt) 20120040114 suspensão de microcápsulas em uma fase líquida aquosa, que permite a liberação modificada de pelo menos um princípio ativo com exclusão da amoxicilina e que é destinada a ser administrada por via oral
ES2838816T3 (es) Composición farmacéutica o nutracéutica con resistencia contra la influencia de etanol
JP6598841B2 (ja) ツーピース硬カプセル用の耐酸性バンド溶液
CA2639921A1 (en) Microspheres comprising nanocapsules containing a lipophilic drug
EP3137057B1 (en) Extended release liquid compositions of metformin
AU2023210558A1 (en) Transdermal delivery formulations
Vidal-Romero et al. Design and evaluation of pH-dependent nanosystems based on cellulose acetate phthalate, nanoparticles loaded with chlorhexidine for periodontal treatment
US11504345B2 (en) Extended release liquid compositions of metformin
Gupta et al. A review on: sustained release technology
EP2604256A1 (en) Multi layer coatings
EP1734933B1 (en) Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
CA2543497A1 (en) Controlled release analgesic suspensions
EA038558B1 (ru) Водорастворимая фармацевтическая пленка с повышенной стабильностью
CN101642443B (zh) 单硝酸异山梨酯渗透泵型控释制剂及其制备方法
CA2490683A1 (en) Coating suspensions (comprising osmopolymers, osmagents) for forming an expandable osmotic composition in controlled release dosage forms as well as the corresponding method for providing this osmotic coating
CN104869985A (zh) 硝酸氨基烷基酯的延长释放组合物
EP2808019B1 (en) Improved nitazoxanide composition and preparation method thereof
JP7212623B2 (ja) 構造化口腔内分散性フィルム